{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:23:40Z","timestamp":1787649820906,"version":"build-2736575974"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Poorly cohesive gastric cancer (PCGC) represents a biologically distinct subtype of gastric cancer, characterized by diffuse growth, marked intratumoral heterogeneity, and a consistently worse prognosis compared with other histological subtypes. Despite advances in pathological classification and molecular profiling, treatment strategies remain largely independent of histological subtype, and no specific therapeutic approaches have been established for PCGC. In this review, we summarize current evidence on the biological features, diagnostic challenges, and emerging therapeutic strategies, with a focus on novel targeted agents and innovative treatment platforms. Recent years have witnessed the development of therapies directed against specific molecular targets, including HER2, PD-L1, CLDN18.2, FGFR2b, and TROP2, as well as the introduction of antibody\u2013drug conjugates and bispecific antibodies, progressively expanding the therapeutic landscape of gastric cancer. However, their clinical impact in poorly cohesive tumors remains to be fully defined. In parallel, advances in digital pathology, artificial intelligence, and multi-omics approaches are providing new opportunities to improve diagnostic reproducibility, refine prognostic stratification, and support personalized treatment strategies by integrating histomorphological and molecular tumor features. Overall, the convergence of novel therapeutic strategies and advanced diagnostic technologies may pave the way toward a more precise and biologically informed management of PCGC, although further validation and integration into clinical practice are required.<\/jats:p>","DOI":"10.3389\/fonc.2026.1842715","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:06:03Z","timestamp":1787648763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative pathological and therapeutic approaches for poorly cohesive gastric cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Margherita","family":"Muratore","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giulio","family":"Sullo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bittoni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Cardisciani","sequence":"additional","affiliation":[{"name":"Pathology Unit, Santa Maria delle Croci Hospital","place":["Ravenna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Valgiusti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Molinari","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, FC, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Camara","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, FC, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Passardi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per Lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","article-title":"WHO classification of tumours, 5th edition, volume 1","volume-title":"Digestive System Tumours","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-018-0868-0","article-title":"Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma","volume":"22","author":"Mariette","year":"2019","journal-title":"Gastric Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-023-01390-5","article-title":"Molecular profile of poorly cohesive gastric carcinoma with special reference to survival","volume":"26","author":"Koseki","year":"2023","journal-title":"Gastric Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J Control Release"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8169","article-title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","volume":"7","author":"B\u00f6ger","year":"2016","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231217967","article-title":"Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer","volume":"16","author":"Kubota","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B9","article-title":"Immunohistochemical detection of K-sam protein in stomach cancer","volume":"2","author":"Hattori","year":"1996","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.09.08","article-title":"Does histology really influence gastric cancer prognosis","volume":"8","author":"Luu","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215191","article-title":"Clinical features of gastric signet ring cell cancer: results from a systematic review and meta-analysis","volume":"15","author":"Dal Cero","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.14670\/HH-18-309","article-title":"Is there still a place for conventional histopathology in the age of molecular medicine","volume":"36","author":"D\u00edaz Del Arco","year":"2021","journal-title":"Histol Histopathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0862-6","article-title":"Solid-type poorly differentiated adenocarcinoma of the stomach: clinicopathological and molecular characteristics and histogenesis","volume":"22","author":"Arai","year":"2019","journal-title":"Gastric Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3109\/03009739909178964","article-title":"Poorly differentiated, solid-type adenocarcinoma of the stomach","volume":"104","author":"Yokota","year":"1999","journal-title":"Ups J Med Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.897218","article-title":"The percentage of signet ring cells is inversely related to aggressive behavior and poor prognosis in mixed-type gastric cancer","volume":"12","author":"Marano","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/a-1007-1730","article-title":"Optimal number of endoscopic biopsies for diagnosis of early gastric cancer","volume":"7","author":"Nishitani","year":"2019","journal-title":"Endosc Int Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03661-z","article-title":"Impact of formalin fixation on mismatch repair protein evaluation by immunohistochemistry","volume":"483","author":"Grillo","year":"2023","journal-title":"Virchows Arch"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.07.026","article-title":"Impact of specimen characteristics on PD-L1 testing in non-small cell lung cancer","volume":"14","author":"Gagn\u00e9","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100159","article-title":"Tissue age affects antigenicity and scoring for the 22C3 immunohistochemistry companion diagnostic test","volume":"36","author":"Fernandez","year":"2023","journal-title":"Mod Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9057-1","article-title":"HER-2\/neu amplification is an independent prognostic factor in gastric cancer","volume":"51","author":"Park","year":"2006","journal-title":"Dig Dis Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1200\/JCO.2007.25.18_suppl.15057","article-title":"HER2 positivity in advanced gastric cancer is comparable to breast cancer","volume":"25","author":"Leon-Chong","year":"2007","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D","article-title":"Mutations of the human E-cadherin (CDH1) gene","volume":"12","author":"Berx","year":"1998","journal-title":"Hum Mutat"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for HER2-positive advanced gastro-oesophageal adenocarcinoma: phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285","article-title":"Zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive gastroesophageal adenocarcinoma: primary analysis from HERIZON-GEA-01","volume":"44","author":"Elimova","year":"2026","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41525-025-00465-9","article-title":"PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome","volume":"10","author":"Chen","year":"2025","journal-title":"NPJ Genom Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double-blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100793","article-title":"Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab","volume":"38","author":"Moehler","year":"2025","journal-title":"Mod Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/s41598-019-41177-2","article-title":"PD-L1 expression combined with microsatellite instability\/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer","volume":"9","author":"Morihiro","year":"2019","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182692","article-title":"PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis","volume":"12","author":"Gu","year":"2017","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn3774","article-title":"Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer","volume":"8","author":"Qin","year":"2022","journal-title":"Sci Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41698-025-01052-y","article-title":"Immunotherapy for diffuse gastric cancer: challenges and new avenues","volume":"9","author":"Zhou","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2612083","article-title":"Clinical response of immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in advanced signet-ring-cell gastric cancer","volume":"22","author":"Liang","year":"2026","journal-title":"Future Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22596","DOI":"10.1038\/s41598-024-73062-y","article-title":"Integrated analysis to identify biological features and molecular markers of poorly cohesive gastric carcinoma (PCC)","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010024","article-title":"Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies","volume":"13","author":"Veas Rodriguez","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2026.02.003","article-title":"Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649","volume":"37","author":"Janjigian","year":"2026","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1466","article-title":"Final overall survival for the phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive advanced, unresectable or metastatic gastric\/gastroesophageal junction adenocarcinoma","volume":"35","author":"Janjigian","year":"2024","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115521","article-title":"Navigating the clinical challenges of zolbetuximab in patients with claudin-positive advanced gastric cancer","volume":"224","author":"Rosanu","year":"2025","journal-title":"Eur J Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"39072","DOI":"10.1038\/s41598-025-26388-0","article-title":"Prognostic significance of claudin 18.2 expression in patients with gastric cancer","volume":"15","author":"Miki","year":"2025","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251369042","article-title":"Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in HER2-negative gastric\/gastroesophageal junction cancer","volume":"17","author":"Zhang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10120-024-01566-7","article-title":"Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab plus EOX versus EOX alone for first-line treatment of CLDN18.2-positive gastric cancer","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive gastric cancer (SPOTLIGHT): a phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155628","article-title":"Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters","volume":"263","author":"Kim","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric cancer","volume":"11","author":"Pellino","year":"2021","journal-title":"J Pers Med"},{"key":"B71","article-title":"A study of TST001 (osemitamab) as monotherapy and in combination with nivolumab and\/or chemotherapy in advanced solid tumors (TranStar102)","year":""},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04306-9","article-title":"First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial","volume":"32","author":"Shitara","year":"2026","journal-title":"Nat Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.01.003","article-title":"Fibroblast growth factor signaling in tumorigenesis","volume":"16","author":"Grose","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.12.002","article-title":"Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma","volume":"43","author":"Jung","year":"2012","journal-title":"Hum Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Matsumoto","year":"2012","journal-title":"Br J Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer","volume":"110","author":"Su","year":"2014","journal-title":"Br J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29184","article-title":"Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis","volume":"10","author":"Kim","year":"2019","journal-title":"J Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31080321","article-title":"Deciphering the FGFR2 code: innovative targets in gastric cancer therapy","volume":"31","author":"Tojjari","year":"2024","journal-title":"Curr Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12953","article-title":"Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers","volume":"8","author":"Seo","year":"2017","journal-title":"Oncotarget"},{"key":"B82","article-title":"Amplification of FGFR2 gene in patients with advanced gastric cancer receiving chemotherapy: prevalence and prognostic significance","volume":"35","author":"Shoji","year":"2015","journal-title":"Anticancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7782","article-title":"Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma","volume":"7","author":"Tokunaga","year":"2016","journal-title":"Oncotarget"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass IIIb and IIIc in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1159\/000441149","article-title":"Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer","volume":"82","author":"Han","year":"2015","journal-title":"Pathobiology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of AZD4547 monotherapy versus paclitaxel in advanced gastric adenocarcinoma with FGFR2 alterations","volume":"28","author":"Van Cutsem","year":"2017","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad149","article-title":"Futibatinib, an irreversible FGFR1\u20134 inhibitor for the treatment of FGFR-aberrant tumors","volume":"28","author":"Javle","year":"2023","journal-title":"Oncologist"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115262","article-title":"Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification","volume":"218","author":"Satoh","year":"2025","journal-title":"Eur J Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1439","article-title":"Efficacy and safety of infigratinib in FGFR2-amplified gastric cancer","volume":"34","author":"Yuan","year":"2023","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-024-00669-3","article-title":"A case of treatment-resistant advanced gastric cancer with FGFR2 gene alteration successfully treated with pemigatinib","volume":"13","author":"Shinomiya","year":"2024","journal-title":"Int Cancer Conf J"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for cancer treatment","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in FGFR2b-selected gastric or gastroesophageal junction adenocarcinoma (FIGHT): a phase 2 trial","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01516-3","article-title":"Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing gastric or gastroesophageal junction cancer: subgroup analysis of the FIGHT trial","volume":"27","author":"Kang","year":"2024","journal-title":"Gastric Cancer"},{"key":"B96","article-title":"Bemarituzumab plus chemotherapy for FGFR2b-overexpressing gastric or gastroesophageal junction cancer: results from the FORTITUDE-101 phase 3 study","author":"Rha","year":"2025"},{"key":"B97","doi-asserted-by":"publisher","first-page":"A033","DOI":"10.1158\/1535-7163.TARG-19-A033","article-title":"Evaluation of FGFR2b in context of relevant biomarkers supports potential combination of anti-FGFR2b with anti-PD-(L)1 therapy in gastric cancer","volume":"18","author":"Sharma","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity and resistance mechanisms","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051117","article-title":"Clinical developments and challenges in treating FGFR2-driven gastric cancer","volume":"12","author":"Lau","year":"2024","journal-title":"Biomedicines"},{"key":"B100","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12032-019-1246-4","article-title":"Deficiency of mismatch repair genes is less frequently observed in signet ring cell compared with non-signet ring cell gastric cancer","volume":"36","author":"Hirotsu","year":"2019","journal-title":"Med Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized dMMR\/MSI-high gastric or gastroesophageal junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management in MSI-high gastric or gastroesophageal junction adenocarcinoma: the INFINITY study","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"B103","article-title":"A study of zolbetuximab in combination with pembrolizumab and chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma (LUCERNE)","year":""},{"key":"B104","article-title":"A study of osemitamab (TST001) in combination with pembrolizumab and chemotherapy as first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma","year":""},{"key":"B105","article-title":"A study of bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab in previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b overexpression (FORTITUDE-102)","year":""},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13101445","article-title":"The impact of trophoblast cell-surface antigen 2 expression on survival in gastrointestinal tumors: a systematic review","volume":"13","author":"Liatsou","year":"2023","journal-title":"J Pers Med"},{"key":"B107","article-title":"A study of sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab and chemotherapy in advanced solid tumors (KEYMAKER-U06)","year":""},{"key":"B108","article-title":"A study of sacituzumab tirumotecan (MK-2870) in advanced solid tumors","year":""},{"key":"B109","article-title":"Study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anti-cancer agents in advanced solid tumours (TROPION-PanTumor03)","year":""},{"key":"B110","article-title":"A study of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophageal adenocarcinoma","year":""},{"key":"B111","article-title":"A study of TJ033721 in subjects with advanced solid tumors","year":""},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.404","article-title":"Preliminary safety and efficacy of givastomig, a novel claudin 18.2\/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma","volume":"36","author":"Klempner","year":"2025","journal-title":"Ann Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41379-021-00919-2","article-title":"Digital pathology and artificial intelligence in translational medicine and clinical practice","volume":"35","author":"Baxi","year":"2022","journal-title":"Mod Pathol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102111","article-title":"Implementation of digital pathology and artificial intelligence in routine pathology practice","volume":"104","author":"Zhang","year":"2024","journal-title":"Lab Invest"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2023.23.e25","article-title":"Artificial intelligence in the pathology of gastric cancer","volume":"23","author":"Choi","year":"2023","journal-title":"J Gastric Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology \u2014 new tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1109\/TAFFC.2026.3698795","article-title":"PersoMoni: A comprehensive video-based benchmark dataset for fine-grained personality assessment with 15 trait dimensions","volume":"1","author":"Cui","year":"2026","journal-title":"IEEE Trans Affect Comput"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1109\/TDSC.2026.3668275","article-title":"Identifying who you are no matter what you write through abstracting handwriting style","volume":"23","author":"Huang","year":"2026","journal-title":"IEEE Trans Dependable Secure Comput"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1437252","article-title":"Applications of artificial intelligence in digital pathology for gastric cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"15330338211027901","DOI":"10.1177\/15330338211027901","article-title":"Deep learning models for gastric signet ring cell carcinoma classification in whole slide images","volume":"20","author":"Kanavati","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-023-01398-x","article-title":"Deep learning-based subtyping of gastric cancer histology predicts clinical outcome: a multi-institutional retrospective study","volume":"26","author":"Veldhuizen","year":"2023","journal-title":"Gastric Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40644-020-00358-3","article-title":"Intratumoral and peritumoral radiomics analysis for preoperative Lauren classification in gastric cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Cancer Imaging"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103631","article-title":"Accurate diagnosis and prognosis prediction of gastric cancer using deep learning on digital pathological images: a retrospective multicentre study","volume":"73","author":"Huang","year":"2021","journal-title":"EBioMedicine"},{"key":"B124","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12967-023-04838-5","article-title":"DeepRisk network: an AI-based tool for digital pathology signature and treatment responsiveness of gastric cancer using whole-slide images","volume":"22","author":"Tian","year":"2024","journal-title":"J Transl Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12967-024-05262-z","article-title":"Deep learning-based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1186\/s12967-025-06181-3","article-title":"Computational pathology approach for assessment of prognosis and immunotherapy response in pan-gastrointestinal cancer","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3934\/medsci.2025024","article-title":"Harnessing big data in pathology for precision medicine in gastric cancer: AI-integrated clinical applications","volume":"12","author":"Ma","year":"2025","journal-title":"AIMS Med Sci"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113064","article-title":"Deep learning for multiclass tumor cell detection in histopathology slides of hereditary diffuse gastric cancer","volume":"28","author":"Lomans","year":"2025","journal-title":"iScience"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1486140","article-title":"Digital pathology-based artificial intelligence model to predict microsatellite instability in gastroesophageal junction adenocarcinomas","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101848","article-title":"Interpretable multi-modal artificial intelligence model for predicting gastric cancer response to neoadjuvant chemotherapy","volume":"5","author":"Gao","year":"2024","journal-title":"Cell Rep Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0605","article-title":"Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression","volume":"15","author":"Ma","year":"2025","journal-title":"Cancer Discov"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413019","article-title":"Spatial and single-cell transcriptomic architecture of cancer stem cell niche in gastric cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12387","article-title":"Clinicopathological features and transcriptomic profiling of poorly cohesive gastric carcinoma subtypes","volume":"10","author":"Yen","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2511.08573","article-title":"Integrating spatial transcriptomics and histopathology with cross-attention encoder for region identification in cancer pathology","author":"Liyanaarachchi","year":"2025","journal-title":"arXiv"},{"key":"B135","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1148\/radiol.2020192224","article-title":"Preparing medical imaging data for machine learning","volume":"295","author":"Willemink","year":"2020","journal-title":"Radiology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1842715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:06:06Z","timestamp":1787648766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1842715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":135,"alternative-id":["10.3389\/fonc.2026.1842715"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1842715","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1842715"}}